Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INNT

Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis

Innovate Biopharmaceuticals logo

About Innovate Biopharmaceuticals Stock (NASDAQ:INNT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.56
$1.42
52-Week Range
N/A
Volume
200 shs
Average Volume
525,982 shs
Market Capitalization
$8 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Receive INNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INNT Stock News Headlines

The DOJ Just Paved the Way for Account Seizures
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
See More Headlines

INNT Stock Analysis - Frequently Asked Questions

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.11).

Based on aggregate information from My MarketBeat watchlists, some other companies that Innovate Biopharmaceuticals investors own include 9 Meters Biopharma (NMTR), NIO (NIO), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET), Iterum Therapeutics (ITRM), Meta Platforms (META) and Micron Technology (MU).

Company Calendar

Last Earnings
3/18/2019
Today
6/07/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INNT
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.05 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.27) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$8 thousand
Optionable
Not Optionable
Beta
-0.39
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:INNT) was last updated on 6/7/2025 by MarketBeat.com Staff
From Our Partners